Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating

Craig-Hallum analyst Chase Knickerbocker maintains $DiaMedica Therapeutics(DMAC.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.7% and a total average return of

Moomoo NewsJun 27 09:32 ET · Ratings

Strategic Announcements Propel DiaMedica (DMAC) Stock Surge

Following a couple of strategic developments, DiaMedica Therapeutics Inc.'s (NASDAQ: DMAC) shares are surging on US stock charts today. As of the most recent check, DMAC stock has gained 30.97% during the current-market session, reaching $2.96. Agreement Details DiaMedica (DMAC) has signed definitive agreements to offer its common shares to accredited investors in a private ...

Stocks TelegraphJun 26 12:49 ET

Express News | DiaMedica Therapeutics Shares Are Trading Higher. The Company Announced a $11.8 Million Private Placement and Will Issue 4.720 Million Shares at $2.50 per Share

BenzingaJun 26 11:19 ET

Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7

Lake Street analyst Thomas Flaten maintains $DiaMedica Therapeutics(DMAC.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 35.1

Moomoo NewsJun 26 09:32 ET · Ratings

Express News | DiaMedica: Will Issue 4.72 Mln Shares at $2.50/Share

ReutersJun 26 08:15 ET

Express News | DiaMedica Therapeutics Inc - Financing to Extend Diamedica’s Cash Runway Into Q3 2026

ReutersJun 26 08:15 ET